Panelists Explore What Exactly Is Holding Up US Adoption of Biosimilars
Payer intervention, lack of patient savings, and confusion surrounding interchangeability are some of the many barriers standing in the way of US biosimilar uptake, with our group of panelists calling for big changes.
Big changes are needed to overcome barriers to US biosimilar adoption, including those involving payers intervening in formulary decisions, confusion regarding interchangeability, and issues with disseminating biosimilar education, according to panelists in a recent webinar.
The webinar, titled “
Limiting Provider Choice and Patient Savings
Although there are cases where providers choose not to prescribe biosimilars, physicians often have a limited
Providers may be forced to fight harder for their patients to receive the biologic that works best for them and prevent them from experiencing the
In addition, sometimes the savings stemming from biosimilar utilization don’t have an impact on patient costs, further contributing to challenges with
“Some of our oncology patients are sometimes on 3 different biologics, and that is so expensive. Often, they're thinking of selling their house or thinking, ‘Should I even get treatment because I may leave nothing for my kids?' And solving that issue for our patients is really what I wish for,” he expressed.
The Confusing World of Interchangeability and Education
“We still hear periodically from different provider types or even pharmacies across the country that when they're valuing biosimilars, they might say, ‘Oh, we're going to wait until they're interchangeable.’ And we know for many of these products, they might be waiting a lifetime, unless the FDA changes the path to achieve that designation. So, there's still quite a bit of
In addition to miscommunication on interchangeability, calls to action for
“There is potential to see some more medical education around biosimilars even at different [health care conferences]…where you don't see a lot of information around biosimilars…. And I feel like the FDA has created resources but haven't really created the construct to engage with those frontline providers, especially in the communities that might have competing priorities,” Haumschild noted.
Will the US Ever Catch Up to the EU?
In the European Union, patients see lower prices for the same drugs marketed in the United States, and the region has had a
Additionally, many European countries have
“When you look at European prices vs US prices, in Europe, lower pricing, not lower cost, actually gets you the bid. The government doesn't act as a middleman where you have to bribe them. You just offer it at a lower percentage. Whereas, in the US it's a perverse incentive to raise prices…. So, the approval process is great to talk about, and I think we need to applaud the FDA for what they've done. But to get those less expensive medications into the hands of the patient is going to require a little bit of an upheaval in the drug supply chain,” explained Feldman.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Iron Dysregulation Linked to MS Progression, Review Finds
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025